A team of researchers led by a team at Weill Cornell Medicine developed a new preclinical mouse model using CRISPR, giving them a deeper insight into how prostate cancer spreads or metastasizes. The model reveals the routes prostate cancer metastatic cells take as they travel through the body. Their findings are detailed in in an article titled, “ .
” “The patterns by which primary tumors spread to metastatic sites remain poorly understood,” the researchers wrote. “Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes.” “Using virtual maps, we can reveal the hidden highways of metastases, one day guiding us toward novel therapies that could act as roadblocks for cancer,” explained study senior author Dawid Nowak, PhD, assistant professor of pharmacology in medicine and the Walter B.
Wriston Research Scholar in Medicine at Weill Cornell Medicine. Approximately 12% of men receive a prostate cancer diagnosis in their lifetime. The American Cancer Society predicts about 35,250 deaths from the disease will occur in 2024 in the United States.
“Prostate cancer that spreads to the lungs, liver, and bones has the most impact on survival,” said lead study author Ryan Serio, PhD, a postdoctoral associate in medicine at Weill Cornell Medicine. When prostate cancer is confined to the primary t.
